Revenue expanded to the 52,247 million yen range (14.9% YoY increase); operating income reached the 3,009 million yen range; quarterly net income attributable to owners of the parent exceeded 2,006 million yen. Full-year forecasts for the fiscal year ending November 2026 are revenue 68,000 million yen, operating income 3,400 million yen, and net income 2,350 million yen. Segment contributions came from Fine Chemicals, HB C & Food, Pharmaceuticals, and Chemicals. Dividend forecast is 18 yen per year. Financial summary and supplementary briefing materials have been published.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"8095","jir_company_name":"Astena Holdings Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-13","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/8095-20261013-01.pdf","jir_short_summary":"Revenue expanded to the 52,247 million yen range (14.9% YoY increase); operating income reached the 3,009 million yen range; quarterly net income attributable to owners of the parent exceeded 2,006 million yen. Full-year forecasts for the fiscal year ending November 2026 are revenue 68,000 million yen, operating income 3,400 million yen, and net income 2,350 million yen. Segment contributions came from Fine Chemicals, HB C & Food, Pharmaceuticals, and Chemicals. Dividend forecast is 18 yen per year. Financial summary and supplementary briefing materials have been published.","jir_summary":"### Overview of Results\nDuring the cumulative third quarter period of the fiscal year ending November 2026, the Group recorded revenue of 52,247 million yen (14.9% increase year-over-year), operating income of 3,009 million yen, ordinary income of 2,799 million yen, and quarterly net income attributable to owners of the parent of 2,006 million yen, securing year-on-year profit growth. By segment, Fine Chemicals, HB C & Food, Pharmaceuticals, and Chemicals contributed, with particularly strong demand in chemicals and surface treatment-related areas driving higher revenue and profit. Supplementary materials are available; the full-year forecast remains revenue 68,000 million yen, operating income 3,400 million yen, and net income 2,350 million yen.\n\n### Impact on Shareholders and Outlook\nThe latest dividend forecast is an annual dividend of 18 yen for the fiscal year ending November 2026, with interim and fiscal dividends of 9 yen each, totaling 18 yen for the year. No earnings briefing was held, but supplementary materials have been released. Going forward, while being exposed to factors such as raw material costs, SG&A trends, and exchange rate fluctuations, the Company expects to maintain growth through expansion of each segment and acquisition of new projects, supported by its medium- to long-term vision and medium-term management plan.","jir_financial_highlights":"Revenue: 52,247 (Year-over-Year 14.9% increase)\nOperating Income: 3,009 (Year-over-Year 7.3% increase)\nOrdinary Income: 2,799 (Year-over-Year 3.1% increase)\nQuarterly Net Income Attributable to Owners of Parent: 2,006 (Year-over-Year 22.7% increase)\nFull-year Revenue Forecast: 68,000 (No change from previous forecast)","jir_category":"","jir_hashtags":"#AstenaHoldings, #Earnings, #MediumTermPlan","jir_key_figures":"Revenue: 52,247 million yen (Year-over-Year 14.9% increase)\nOperating Income: 3,009 million yen (Year-over-Year 7.3% increase)\nQuarterly Net Income Attributable to Owners of Parent: 2,006 million yen (Year-over-Year 22.7% increase)","jir_meta_title":"Astena Holdings Co., Ltd. - Third Quarter Financial Summary for Fiscal Year Ending November 2026 | Revenue 52,247 million yen (YoY +14.9%)","jir_meta_description":"Key points of Astena Holdings Co., Ltd.'s third quarter financial summary for the fiscal year ending November 2026: revenue 52,247 million yen, operating income over 3,000 million yen, net income over 2,000 million yen. Includes segment trends and full-year outlook.","jir_og_title":"Astena Holdings Co., Ltd. Q3 Financial Results: Revenue 52,247 million yen","jir_og_description":"Key points of Astena Holdings Co., Ltd.'s third quarter financial summary for the fiscal year ending November 2026. Revenue 52,247 million yen, a 14.9% increase year-over-year.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025\/11\\\",\\\"2026\/11\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[45247,52247],\\\"borderColor\\\":\\\"#3e95cd\\\",\\\"fill\\\":false}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025\/11\\\",\\\"2026\/11\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[2803,3009],\\\"borderColor\\\":\\\"#8e5ea2\\\",\\\"fill\\\":false}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"net_income_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Quarterly Net Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025\/11\\\",\\\"2026\/11\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Income\\\",\\\"data\\\":[1635,2006],\\\"borderColor\\\":\\\"#3cba9f\\\",\\\"fill\\\":false}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Revenue Breakdown\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Fine Chemicals\\\",\\\"HB C & Food\\\",\\\"Pharmaceuticals\\\",\\\"Chemicals\\\",\\\"Other\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[17852,17031,12597,9161,0],\\\"backgroundColor\\\":[\\\"#3e95cd\\\",\\\"#8e5ea2\\\",\\\"#e8c3b9\\\",\\\"#c45850\\\",\\\"#a9d0f5\\\"]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Margin Analysis\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Fine Chemicals\\\",\\\"HB C & Food\\\",\\\"Pharmaceuticals\\\",\\\"Chemicals\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Segment Profit\\\",\\n \\\"data\\\":[1080,984,897,0],\\\"backgroundColor\\\":[\\\"#3e95cd\\\",\\\"#8e5ea2\\\",\\\"#e8c3b9\\\",\\\"#c45850\\\"]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Guidance vs. Actual Comparison\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Revenue\\\",\\\"Operating Income\\\",\\\"Ordinary Income\\\",\\\"Net Income\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Guidance\\\",\\\"data\\\":[68000,3400,3300,2350],\\\"borderColor\\\":\\\"#3e95cd\\\",\\\"fill\\\":false},{\\\"label\\\":\\\"Actual\\\",\\\"data\\\":[52247,3009,2799,2006],\\\"borderColor\\\":\\\"#8e5ea2\\\",\\\"fill\\\":false}]},\\\"options\\\":{}}\"}]","ir_related_company":57913,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-129497","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n